Gastroenterology and Clinical Nutrition, St Elisabeth Hospital, Katharina Kasper Clinics, Teaching Hospital of the Goethe University Frankfurt, Ginnheimer Street 3, D-60487 Frankfurt, Germany.
Nat Rev Gastroenterol Hepatol. 2010 Nov;7(11):599-610. doi: 10.1038/nrgastro.2010.151. Epub 2010 Oct 5.
Anemia is the most prevalent extraintestinal complication of IBD. It can affect quality of life and ability to work, and can also increase the hospitalization rate in patients with IBD. Although the causes of anemia in IBD are multifactorial, iron deficiency anemia (IDA) is the most common. Assessment of the iron status of patients who have a condition associated with inflammation, such as IBD, by using common biochemical values is insufficient. However, new indices of iron metabolism (for instance ferritin:transferrin receptor ratio, reticulocyte hemoglobin content or percentage of hypochromic red blood cells) may help to improve the assessment of iron status in patients with IBD. The treatment of IDA traditionally involves oral iron supplementation. However, because of extensive gastrointestinal adverse effects, and data showing that the use of oral iron in IBD may be associated with disease exacerbation, current guidelines suggest that iron supplementation in IBD should be administered intravenously. This Review provides an overview of iron homeostasis in health before discussing diagnostic and therapeutic strategies for IDA in patients with IBD.
贫血是 IBD 最常见的肠道外并发症。它会影响生活质量和工作能力,也会增加 IBD 患者的住院率。尽管 IBD 患者贫血的原因是多因素的,但缺铁性贫血(IDA)最为常见。通过常用的生化值评估存在炎症相关疾病(如 IBD)的患者的铁状态是不够的。然而,新的铁代谢指标(例如铁蛋白:转铁蛋白受体比值、网织红细胞血红蛋白含量或低色素红细胞的百分比)可能有助于改善 IBD 患者铁状态的评估。IDA 的传统治疗方法包括口服铁补充剂。但是,由于广泛的胃肠道不良反应,并且数据表明 IBD 患者使用口服铁可能与疾病恶化有关,因此目前的指南建议 IBD 患者的铁补充应通过静脉内给药。这篇综述在讨论 IBD 患者 IDA 的诊断和治疗策略之前,先概述了健康状态下的铁稳态。